Transcatheter and Surgical Aortic Valve Replacement Outcomes for Patients with Chronic Heart Failure

2020 ◽  
Author(s):  
Talha Mubashir ◽  
Julius Balogh ◽  
Rabail Chaudhry ◽  
Cooper Quiroz ◽  
Biswajit Kar ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Surgical Aortic Valve Replacement

scholarly journals OUTCOMES OF TRANSCATHETER VS. SURGICAL AORTIC VALVE REPLACEMENT IN OCTOGENARIANS WITH HEART FAILURE

2021 ◽  
Vol 77 (18) ◽  
pp. 1167
Author(s):  
Yasar Sattar ◽  
Bachar Ahmad ◽  
Junaid Arshad ◽  
Uneza Khawaja ◽  
Abdul-Rahman M. Suleiman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Surgical Aortic Valve Replacement

Cardiac resynchronisation therapy for reversal of new-onset left bundle branch block and heart failure after surgical aortic valve replacement

2020 ◽  
Vol 13 (12) ◽  
pp. e238130
Author(s):  
Mandeep Singh Kalsi ◽  
Nalin Dayawansa ◽  
Vivek Mutha
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Left Bundle Branch Block ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Surgical Aortic Valve Replacement ◽  
Bundle Branch Block ◽  
Transcatheter Aortic Valve

Left bundle branch block (LBBB) is not an uncommon complication following both surgical aortic valve replacement and transcatheter aortic valve implantation. LBBB can cause interventricular and intraventricular dyssynchrony that can lead to development of heart failure as demonstrated by a decline in left ventricular ejection fraction (LVEF). It is known that change in QRS duration has significant correlation with change in LVEF. In a study involving 202 consecutive patients with no baseline ventricular conduction disturbances or previous permanent pacemaker implantation who underwent transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve, it was found that around 30% of patients develop new LBBB.

Abstract 14935: Impact of Paravalvular Regurgitation after Surgical Aortic Valve Replacement for Severe Aortic Stenosis: An Intraoperative Transesophageal Echocardiography Study

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Hirotsugu Mihara ◽  
Javier Berdejo ◽  
Yuji Itabashi ◽  
Hiroto Utsunomiya ◽  
Michele A De Robertis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Color Doppler ◽  
Surgical Aortic Valve Replacement ◽  
Intraoperative Transesophageal Echocardiography ◽  
Heart Failure Exacerbation ◽  
The Impact

Introduction: Greater than mild paravalvular regurgitation (PVR) is reported to worsen late mortality after transcatheter aortic valve replacement (TAVR). However the impact of PVR on the prognosis after surgical aortic valve replacement (SAVR) is not determined. The purpose of this study was to investigate the impact of PVR on the prognosis after SAVR in patients with aortic stenosis (AS) using intraoperative transesophageal echocardiography (iTEE). Hypothesis: We hypothesized that the prognosis of mild PVR after SAVR in patients with AS is benign. Methods: We retrospectively reviewed 304 consecutive patients with severe AS who underwent isolated SAVR using bioprosthesis and who had color Doppler iTEE images after SAVR. Severity of PVR was determined by the sum of the cross-sectional area of the vena contracta (VCA) using 2D color Doppler just after SAVR. Grading of PVR was determined using the following VCA cutoffs: trivial 0-4 mm2; mild 5-9 mm2; moderate 10-29 mm2; severe ≥ 30 mm2. We investigated the clinical course after SAVR including death, re-hospitalization due to heart failure exacerbation, and reoperation. Results: The patients were 76 ± 10 years old, and 57% were male. PVR was trivial in 28 patients (9%), mild in 18 (6%), moderate in 9 (3%), severe in 0. During the follow-up period of 1111 ± 582 days (median 1071 days), there were significant differences in survival between moderate and none/trivial or mild PVR group (p < 0.001 and 0.004, respectively). There was no significant differences in survival between mild and none/trivial PVR group (p = 0.69). Of 35 patients with ≥ mild PVR, only 3 patients with moderate PAR re-hospitalized for heart failure exacerbation and 1 of them resulted in successful percutaneous paravalvular leak closure. There was no other patient for reoperation except this patient. Conclusions: Although infrequent, moderate PVR showed worse survival following SAVR for severe AS, while the prognosis of mild PVR was benign.

scholarly journals Post-operative Atrial Fibrillation Impacts on Outcomes in Transcatheter and Surgical Aortic Valve Replacement

2021 ◽  
Vol 8 ◽  
Author(s):  
Hyung Ki Jeong ◽  
Namsik Yoon ◽  
Ju Han Kim ◽  
Nuri Lee ◽  
Dae Yong Hyun ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Clinical Outcomes ◽  
Valve Replacement ◽  
Severe Aortic Stenosis ◽  
Composite Outcome ◽  
Surgical Aortic Valve Replacement ◽  
The Impact

Background: Atrial fibrillation (AF) in severe aortic stenosis (AS) has poor outcomes after transcatheter and surgical aortic valve replacement (TAVR and SAVR, respectively). We compared the incidence of AF after aortic valve replacement (AVR) according to the treatment method and the impact of AF on outcomes.Methods: We investigated the incidence of AF and clinical outcomes of AVR according to whether AF occurred after TAVR and SAVR after propensity score (PS)-matching for 1 year follow-up. Clinical outcomes were defined as death, stroke, and admission due to heart failure. The composite outcome comprised death, stroke, and admission due to heart failure.Results: A total of 221 patients with severe AS were enrolled consecutively, 100 of whom underwent TAVR and 121 underwent SAVR. The incidence of newly detected AF was significantly higher in the SAVR group before PS-matching (6.0 vs. 40.5%, P &lt; 0.001) and after PS-matching (7.5 vs. 35.6%, P = 0.001). TAVR and SAVR showed no significant differences in outcomes except in terms of stroke. In the TAVR group, AF history did not affect the outcomes; however, in the SAVR group, AF history affected death (log rank P = 0.038). Post-AVR AF had a worse impact on admission due to heart failure (log rank P = 0.049) and composite outcomes in the SAVR group. Post-AVR AF had a worse impact on admission due to heart failure (log rank P = 0.008) and composite outcome in the TAVR group.Conclusion: Post-AVR AF could be considered as a predictor of the outcomes of AVR. TAVR might be a favorable treatment option for patients with severe symptomatic AS who are at high-risk for AF development or who have a history of AF because the occurrence of AF was more frequent in the SAVR group.

scholarly journals Transcatheter and Surgical Aortic Valve Replacement in Patients With Recent Acute Heart Failure

2020 ◽  
Vol 109 (1) ◽  
pp. 110-117
Author(s):  
Maina P. Jalava ◽  
Teemu Laakso ◽  
Marko Virtanen ◽  
Matti Niemelä ◽  
Tuomas Ahvenvaara ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Acute Heart Failure ◽  
Valve Replacement ◽  
Surgical Aortic Valve Replacement

scholarly journals COMPARATIVE ASSESSMENT OF CLINICAL AND HEMODYNAMIC OUTCOMES AFTER AORTIC HEART VALVE REPLACEMENT WITH XENOAORTIC AND XENOPERICARDIAL BIOLOGICAL PROSTHESES FOR DEGENERATIVE AORTIC VALVULAR DISEASE

2018 ◽  
Vol 7 (2) ◽  
pp. 50-60
Author(s):  
S. A. Fedorov ◽  
A. P. Medvedev ◽  
V. A. Chiginev ◽  
S. A. Zhurko ◽  
A. B. Gamzaev ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
The Mean ◽  
Group 2 ◽  
Biological Prostheses ◽  
Group 1

Aim. To assess clinical and hemodynamic outcomes of aortic valve replacement with xenoaortic biological prosthesis “Aspire Vascutek” and xenopericardial biological prosthesis “UniLine”. Methods. 130 patients who underwent aortic valve replacement with bioprostheses in the period from October 2012 to March 2016 were included in the study. All patients were enrolled into two groups according to the model of the implanted device. 65 recipients of xenoaortic bioprostheses “Aspire Vascutek” were included in Group 1, whereas patients (n = 65) xenopericardial bioprostheses “UniLine” were assigned in Group 2. Males prevailed in Group 1 (63%, the mean age - 66.4±5.5 years). 85% of Group 1 patients had heart failure Strazhesko-Vasilenko IIA grade and 94% of patients had chronic heart failure NYHA III. Similarly, male patients (58%) prevailed in Group 2. The mean age of Group 2 patients was 66.5±3.65 years. All patients in Group 2 II had heart failure Strazhesko-Vasilenko IIA grade and chronic heart failure NYHA III. Results Two patients in Group 1 died in the early postoperative period (the overall mortality was 1.5%). All patients had chronic heart failure NYHA I-II at discharge. Peak transvalvular pressure gradient significantly decreased in the in-hospital period, particularly in Group 2 patients (82,3±22,7 mm Hg vs. 28.8±7.6 mm Hg). 88% of Group 1 patients underwent the 60-month follow-up, and 96% of Group 2 patients - the 48-month follow-up. Transvalvular pressure gradients decreased progressively in both study groups within 60 months follow-up. This decrease was more pronounced in recipients of xenopericardial biological prostheses. Conclusion. Aortic valve replacement with xenopericardial bioprostheses “UniLine” and xenoaortic bioprostheses “Aspire Vascutek” for aortic valvular disease allows treating intracardiac hemodynamic derangements and achieving good clinical and hemodynamic outcomes.

Sign in / Sign up

Export Citation Format

Share Document